Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)

NCT00557830 is registered in ClinicalTrials.gov with Accelerated Community Oncology Research Network as lead sponsor.

NCT NCT00557830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00557830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)
Lead sponsor
Accelerated Community Oncology Research Network
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2008
Completion date
April 30, 2011
Enrollment
12 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma